Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Jim B who wrote (1026)	6/17/1998 3:19:00 PM
From: Gwolf	Respond to of 5402

To all potential new investors........................ If you are a potential new investor in this company I encourage you to ignore the silly prattle that goes on here, unless you're TV is broken and you miss 'Days Of Our Lives'. If you're an investor you really don't care about the individuals on this thread that discuss their personal emotions toward other members. If you are trying to learn about the company please go to the 'information only thread' and read the basics. the next step is to call Dr. Drees the chairman of the company and ask him questions. With this information compiled try to determine the valuation for the company. The next step is to determine if you are a S.T. investor or a L.T. investor or a combination of both. Lastly determine your risk tolerance and your financial assets. If you are speculating limit your capital commitment. If you are an investor with a longer time horizon then you could conceivably increase your exposure. If you have both a S.T. and a L.T. perspective you may consider buying twice your L.T. commitment and selling 1/2 after the stock has appreciated 50% to 100% ( if you think it has that potential)therby reducing the cost of your L.T. position. If you are a new investor ignore the chatter on the thread,do your homework and make a logical investment based on your personal perimeters. REMEMBER - It's your money, no one else's. Gwolf